NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma

Wilson, C. L., Jurk, D., Fullard, N., Banks, P., Page, A., Luli, S., Elsharkawy, A. M., Gieling, Roben, Chakraborty, J. Bagchi, Fox, C., Richardson, C., Callaghan, K., Blair, G. E., Fox, N., Lagnado, A., Passos, J. F., Moore, A. J., Smith, G. R., Tiniakos, D. G., Mann, J., Oakley, F. and Mann, D. A. (2015) NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma. Nature Communications, 6 (1). ISSN 2041-1723

Preview

Text (Full text) Wilson et al - NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma OA.pdf - Published Version Available under License Creative Commons Attribution 4.0. Download (4MB) | Preview

Abstract

Hepatocellular carcinoma (HCC) develops on the background of chronic hepatitis. Leukocytes found within the HCC microenvironment are implicated as regulators of tumour growth. We show that diethylnitrosamine (DEN)-induced murine HCC is attenuated by antibody-mediated depletion of hepatic neutrophils, the latter stimulating hepatocellular ROS and telomere DNA damage. We additionally report a previously unappreciated tumour suppressor function for hepatocellular nfkb1 operating via p50:p50 dimers and the co-repressor HDAC1. These anti-inflammatory proteins combine to transcriptionally repress hepatic expression of a S100A8/9, CXCL1 and CXCL2 neutrophil chemokine network. Loss of nfkb1 promotes ageing-associated chronic liver disease (CLD), characterized by steatosis, neutrophillia, fibrosis, hepatocyte telomere damage and HCC. Nfkb1S340A/S340Amice carrying a mutation designed to selectively disrupt p50:p50:HDAC1 complexes are more susceptible to HCC; by contrast, mice lacking S100A9 express reduced neutrophil chemokines and are protected from HCC. Inhibiting neutrophil accumulation in CLD or targeting their tumour-promoting activities may offer therapeutic opportunities in HCC.

Actions (login required)

View Item

Downloads